Page 80 - Read Online

Page 74 Leung et al. J Transl Genet Genom 2023;7:79-86 https://dx.doi.org/10.20517/jtgg.2023.09

adults. Blood Cancer J 2020;10:104. DOI PubMed PMC
19. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours:
myeloid and histiocytic/dendritic neoplasms. Leukemia 2022;36:1703-19. DOI PubMed PMC
20. Krigstein M, Iland HJ, Wei AH. Applying molecular measurable residual disease testing in acute myeloid leukaemia. Pathology
2023;55:1-7. DOI PubMed
21. Heuser M, Freeman SD, Ossenkoppele GJ, et al. 2021 update on MRD in acute myeloid leukemia: a consensus document from the
European LeukemiaNet MRD working party. Blood 2021;138:2753-67. DOI PubMed PMC
22. Burd A, Levine RL, Ruppert AS, et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling:
feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med 2020;26:1852-8. DOI PubMed PMC
23. Lam SS, Ho ES, He BL, et al. Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia.
Sci Transl Med 2016;8:359ra129. DOI
24. Malani D, Kumar A, Brück O, et al. Implementing a functional precision medicine tumor board for acute myeloid leukemia. Cancer
Discov 2022;12:388-401. DOI PubMed PMC
25. Wang H, Chan KYY, Cheng CK, et al. Pharmacogenomic profiling of pediatric acute myeloid leukemia to identify therapeutic
vulnerabilities and inform functional precision medicine. Blood Cancer Discov 2022;3:516-35. DOI
26. Lilljebjörn H, Orsmark-Pietras C, Mitelman F, Hagström-Andersson A, Fioretos T. Transcriptomics paving the way for improved
diagnostics and precision medicine of acute leukemia. Semin Cancer Biol 2022;84:40-9. DOI PubMed